Quarterly report pursuant to Section 13 or 15(d)

Related Party Agreements (Narrative) (Details)

v3.23.3
Related Party Agreements (Narrative) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Jan. 06, 2023
Jan. 01, 2022
Jul. 22, 2016
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]                
Common stock, shares issuable       6,987   6,987   187,134
General and administrative       $ 2,131 $ 3,389 $ 7,507 $ 9,815  
Research and development       9,477 15,419 34,313 46,872  
Proceeds from debt issuance           0 30,000  
Research and development for licenses acquired       $ 50 40 $ 50 40  
Restricted Stock Awards [Member]                
Related Party Transaction [Line Items]                
Number of shares issued           36,230    
At the Market Offering [Member]                
Related Party Transaction [Line Items]                
Proceeds from issuance of common shares           $ 200 6,600  
Fortress Biotech, Inc [Member]                
Related Party Transaction [Line Items]                
Shares issued for services (in shares) 187,134              
Common stock, shares issuable       1,297   1,297    
Sponsored Research and Clinical Trial Agreements [Member]                
Related Party Transaction [Line Items]                
Research and development       $ 364 1,836 $ 3,739 $ 4,884  
Parent Company | Management Services Agreement (MSA) | Fortress Biotech, Inc [Member]                
Related Party Transaction [Line Items]                
Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses           50.00% 50.00%  
Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses           50.00% 50.00%  
Expenses from related party transaction       100 200 $ 400 $ 800  
Parent Company | Founders Agreement | Fortress Biotech, Inc [Member]                
Related Party Transaction [Line Items]                
Common shares issuable recorded - Founders Agreement           4,000,000    
Percentage of fully diluted equity   2.50% 2.50%          
General and administrative       $ 4,000 $ 18,000 $ 4,000 $ 900  
Research and development for licenses acquired               $ 1,100